Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 6/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | CTSE | P14091 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5876380 | 0.97 | BACE1 (0.40) | KDM1ASHMT1KCNH2OPRD1GAA | |
| SCHEMBL5876731 | 0.86 | BACE1 (0.39) | KCNH2OPRD1GAABACE1BACE2 | |
| SCHEMBL5878004 | 0.85 | GAA (0.37) | GAABACE1BACE2ALDH1A1 | |
| SCHEMBL5876734 | 0.83 | SHMT1 (0.39) | KDM1ASHMT1KCNH2OPRD1GAA | |
| SCHEMBL6806636 | 0.83 | GAA (0.46) | KDM1AOPRD1GAABACE1BACE2 | |
| SCHEMBL6801220 | 0.82 | GAA (0.45) | KDM1AOPRD1GAABACE1BACE2 | |
| SCHEMBL5877068 | 0.82 | KDM4E (0.37) | BACE1BACE2CTSDALDH1A1 | |
| SCHEMBL5878062 | 0.81 | KDM1A (0.36) | KDM1AGAABACE1NOTUM | |
| SCHEMBL5876549 | 0.81 | SMN1; SMN2 (0.41) | GAAALDH1A1 | |
| SCHEMBL6801110 | 0.81 | GAA (0.41) | KCNH2GAABACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119115-B2 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | AVENTIS PHARMA S.A. (FR) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162276-A1 | Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology | IDO1, IDO2, INMT | KDM1A 1958/4885SHMT1 361/4885KCNH2 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.